PRESTIGE CONSUMER HEALTHCARE INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.75 million as of 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-05-14
- 2026-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.75M.
- 2025-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.51M.
- 2024-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.58M.
- 2023-03-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.61M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2026-03-31 | $3.75M 10-K · filed 2026-05-14 |
| 2025-03-31 | $3.51M 10-K · filed 2026-05-14 |
| 2024-03-31 | $3.58M 10-K · filed 2025-05-09 |
| 2023-03-31 | $4.61M 10-K · filed 2024-05-15 |
| 2022-03-31 | $4.55M 10-K · filed 2023-05-05 |
| 2021-03-31 | $4.37M 10-K · filed 2022-05-06 |
| 2020-03-31 | $4.33M 10-K · filed 2021-05-07 |
| 2019-03-31 | $4.21M 10-K · filed 2020-05-08 |
| 2018-03-31 | $5.04M 10-K · filed 2019-05-13 |
| 2017-03-31 | $5.79M 10-K · filed 2018-05-10 |
| 2016-03-31 | $4.41M 10-K · filed 2017-05-17 |
| 2015-03-31 | $3.52M 10-K · filed 2016-05-17 |
| 2014-03-31 | $2.36M 10-K · filed 2015-05-14 |
| 2013-03-31 | $2.37M 10-K · filed 2014-05-19 |
| 2012-03-31 | $2.54M 10-K · filed 2013-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |